Loading…
Edwards Lifesciences Corporation is projected to rise to $98.65 by 2027, a +18% move from its current price of $83.68. EW is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/29/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 31 | $82.64 | $83.71 | $84.79 | +0.03% |
| Aug 1 | $82.23 | $83.74 | $85.26 | +0.07% |
| Aug 2 | $81.93 | $83.76 | $85.64 | +0.10% |
| Aug 3 | $81.67 | $83.79 | $85.96 | +0.13% |
| Aug 4 | $81.45 | $83.82 | $86.25 | +0.16% |
| Aug 5 | $81.26 | $83.85 | $86.52 | +0.20% |
| Aug 6 | $81.08 | $83.87 | $86.76 | +0.23% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $81.08 | $83.87 | $86.76 | +0.23% |
| Week 2 | $80.14 | $84.07 | $88.19 | +0.46% |
| Week 3 | $79.46 | $84.26 | $89.35 | +0.69% |
| Week 4 | $78.92 | $84.45 | $90.37 | +0.93% |
| Week 5 | $78.48 | $84.65 | $91.31 | +1.16% |
| Week 6 | $78.09 | $84.84 | $92.18 | +1.39% |
| Week 7 | $77.75 | $85.04 | $93.01 | +1.63% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve.
It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
EW is a healthcare company with a current price of $87.27. It has a market cap of $50.25B and ranks 317. The forecasted price path shows a rising trajectory through 2030 and beyond, with the 2026 average price at $87.27 and higher averages in subsequent years.
Notable future averages include 2027 $103.45, 2030 $137.33, 2040 $354.85, and 2050 $718.62, along with corresponding maximums such as $187.16 in 2030, $541.22 in 2040, and $1,174.93 in 2050.
A major floor 10.4% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.8% away) — a key level to hold.
The nearest ceiling, 13.7% above — a clean break opens room to run.
A major ceiling 18.6% above — clearing it would confirm fresh momentum.
Key EW support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of EW market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $84.16 | Sell | $84.36 | Sell |
| MA 10 | $86.35 | Sell | $86.00 | Sell |
| MA 20 | $89.47 | Sell | $87.44 | Sell |
| MA 50 | $87.26 | Sell | $87.00 | Sell |
| MA 100 | $84.51 | Sell | $85.44 | Sell |
| MA 200 | $83.43 | Buy | $83.38 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 33.60 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -125.53 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -1.10 | Sell |
| ROC (12) | -11.32 | Sell |
| Bollinger %B (20,2) | 0.08 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.01 | Buy |
| Awesome (5,34) | -4.28 | Sell |
| Ultimate (7,14,28) | 15.52 | Buy |
| Momentum (10) | -9.17 | Sell |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 82.88 | Buy |
| ADX (14) | 21.51 | Sell |
| ATR (14) | 1.07 | Info |
The 30-day picture is bullish with a current RSI(14) of 40. The 50-day simple moving average sits at $86.76, while the 200-day simple moving average is $83.15. The immediate support is at $85.11 and resistance at $95.18. The 30-day price range is $79.38 to $95.94, and annualized volatility sits around 30%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $75.87 | $83.68 | $107.46 | 0% | Neutral | |
| $80.88 | $98.65 | $125.75 | +18% | Neutral | |
| $80.95 | $100.61 | $131.76 | +20% | Bullish | |
| $90.01 | $113.62 | $152.00 | +36% | Bullish | |
| $99.72 | $127.58 | $173.77 | +52% | Bullish | |
| $116.23 | $150.53 | $208.29 | +80% | Bullish | |
| $134.56 | $176.24 | $247.35 | +111% | Bullish | |
| $137.03 | $181.37 | $257.86 | +117% | Bullish | |
| $144.32 | $192.93 | $277.59 | +131% | Bullish | |
| $155.51 | $209.86 | $305.31 | +151% | Bullish | |
| $228.14 | $321.14 | $489.66 | +284% | Bullish | |
| $421.28 | $636.03 | $1,039.67 | +660% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $75.87 | $83.68 | $97.69 | +0.00% |
| August 2026 | $72.36 | $84.41 | $100.38 | +0.87% |
| September 2026 | $73.51 | $86.23 | $103.49 | +2.16% |
| October 2026 | $72.85 | $85.85 | $103.78 | -0.44% |
| November 2026 | $72.29 | $85.51 | $103.99 | -0.40% |
| December 2026 | $74.05 | $87.89 | $107.46 | +2.78% |
Click any year to see its month-by-month EW forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Edwards Lifesciences Corporation's 2026 outlook centres on $83.68, within a $75.87 to $107.46 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, EW could reach as high as $125.75, with a base case around $98.65 and support toward $80.88 — roughly +18% from $83.68. Price action looks broadly range-bound.
Expect EW to range from $80.95 to $131.76 through 2028. The $100.61 average target implies a +20% move from current prices. That is up +2% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The EW price prediction for 2029 points to an average of $113.62 (low $90.01, high $152.00) — a potential gain of +36% on today's $83.68. Momentum favours further upside here.
In 2030, EW is projected to trade between $99.72 and $173.77, averaging $127.58 — a potential gain of +52% from today's $83.68. That is up +12% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Edwards Lifesciences Corporation's 2031 outlook centres on $150.53, within a $116.23 to $208.29 range. That is up +18% on the projected 2030 average. That marks a +80% change versus current levels. Momentum favours further upside here.
By 2032, EW could reach as high as $247.35, with a base case around $176.24 and support toward $134.56 — roughly +111% from $83.68. Buyers look set to stay in control over this stretch.
Expect EW to range from $137.03 to $257.86 through 2033. The $181.37 average target implies a +117% move from current prices. That is up +3% on the projected 2032 average. Momentum favours further upside here.
The EW price prediction for 2034 points to an average of $192.93 (low $144.32, high $277.59) — a potential gain of +131% on today's $83.68. Buyers look set to stay in control over this stretch.
In 2035, EW is projected to trade between $155.51 and $305.31, averaging $209.86 — a potential gain of +151% from today's $83.68. That is up +9% on the projected 2034 average. Momentum favours further upside here.
Edwards Lifesciences Corporation's 2040 outlook centres on $321.14, within a $228.14 to $489.66 range. That is up +53% on the projected 2035 average. That marks a +284% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, EW could reach as high as $1,039.67, with a base case around $636.03 and support toward $421.28 — roughly +660% from $83.68. Momentum favours further upside here.
Investing $1,000 in EW today (≈ 11.950287 EW) could be worth
$7,600.77
+$6,600.77 (+660%) by 2050 · US Dollar
Based on the average projected EW price of $636.03 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in EWwould be worth at today's price.
$1,000 invested in EW on Jul 28, 2025 (≈ 12.740477 EW) would be worth
$1,066.12
+$66.12 (+6.6%) today · 1.07× · US Dollar
Based on a EW entry price of $78.49 vs. today's $83.68.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $85 | $984.47 | -1.6% |
| 1 month ago | $90.78 | $921.79 | -7.8% |
| 3 months ago | $82.28 | $1,017.02 | +1.7% |
| 6 months ago | $81.86 | $1,022.23 | +2.2% |
| 1 year ago | $78.49 | $1,066.12 | +6.6% |
| All time (5.0y) ago | $113.28 | $738.7 | -26.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our EW forecast.
Our base-case forecast reaches $170.00 around 2032.
Implied market cap at $170.00: $97.89B
The multi-year forecast shows a bullish outlook across the future years, with rising average prices such as 2027 at $103.45, 2028 at $106.68, 2029 at $122.33, and 2030 at $137.33. Looking further, 2031 is projected at $163.32, 2032 at $191.81, 2033 at $195.61, 2034 at $210.92, and 2035 at $231.38, extending to 2040 at $354.85 and 2050 at $718.62. The corresponding max prices rise to $187.16 (2030), $541.22 (2040), and $1,174.93 (2050).
Return-on-investment figures accompany these averages, for example 57.4% in 2030, 306.6% in 2040, and 723.5% in 2050, with earlier years showing smaller gains. These are estimates and not guarantees, reflecting potential upside under varied market conditions.
Tap a question to reveal the answer.
Avg $137.33; min $107.29; max $187.16; ROI 57.4%; sentiment BULLISH.
Forecasts show rising averages and notable ROIs in future years (e.g., 2030 ROI 57.4%, 2040 ROI 306.6%, 2050 ROI 723.5%), but these are estimates, not guarantees.
Yes. The forecasted average price for 2027 is $103.45, indicating a path above $100 in the near term.
Low $79.38, High $95.94.
Current price $87.27; Market cap $50.25B; Rank 317.
Edwards Lifesciences Corporation Community Discussion
0Share your Edwards Lifesciences Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.